1 / 8

Longitudinal Nationwide Antimicrobial Susceptibility Surveillance in Ocular Isolates: Results from Ocular TRUST 2

Longitudinal Nationwide Antimicrobial Susceptibility Surveillance in Ocular Isolates: Results from Ocular TRUST 2. Penny A. Asbell, MD 1 Daniel F. Sahm, MD 2 1 Mount Sinai School of Medicine, New York, NY; 2 Eurofins Medinet, Inc, Anti-Infective Services, Herndon, VA.

kyran
Download Presentation

Longitudinal Nationwide Antimicrobial Susceptibility Surveillance in Ocular Isolates: Results from Ocular TRUST 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Longitudinal Nationwide Antimicrobial Susceptibility Surveillance in Ocular Isolates:Results from Ocular TRUST 2 Penny A. Asbell, MD1 Daniel F. Sahm, MD2 1Mount Sinai School of Medicine, New York, NY; 2Eurofins Medinet, Inc, Anti-Infective Services, Herndon, VA Financial Disclosure: Dr. Asbell has served as a consultant to Inspire Pharmaceuticals and has received lecture fees from Alcon Laboratories, Allergan Pharmaceuticals, Santen Pharmaceutical, Inspire Pharmaceuticals, and Vistakon Pharmaceuticals. Dr. Sahm is a full-time employee of Eurofins Medinet, Inc., Anti-Infective Services and has received lecture fees from Vistakon Pharmaceuticals.

  2. Ocular TRUST: Nationwide Antimicrobial Susceptibility Surveillance Program • Ocular isolates only • Initiated in 2005 • Largest surveillance program with centralized in vitro susceptibility testing • Annual surveys providing longitudinal data

  3. Ocular TRUST 2 (2006-2007)

  4. State with participating institution Participating Eye Centers (10) Ocular TRUST: Participating Sites

  5. 100 80 60 40 20 AZI AZI CIP CIP TRI TRI PEN PEN TOB TOB LEV LEV GAT GAT MOX MOX PLYX PLYX Ocular TRUST 2: S. aureus Susceptibility MRSA (N=84) MSSA (N=71) % Susceptible 18

  6. 100 80 60 40 20 AZI AZI CIP CIP TRI TRI PEN PEN TOB TOB LEV LEV GAT GAT MOX MOX PLYX PLYX Ocular TRUST 2: Coagulase-Negative Staphylococci Susceptibility Methicillin-resistant (N=52) Methicillin-susceptible (N=40) 44 % Susceptible

  7. 100 80 60 40 20 AZI AZI CIP CIP TRI TRI PEN PEN TOB TOB LEV LEV GAT GAT MOX MOX PLYX PLYX Ocular TRUST 2: S. pneumoniae and H. influenzae Susceptibility H. influenzae (N=144) S. pneumoniae (N=198) 100 % Susceptible

  8. Ocular TRUST 2: Overview • Methicillin resistance in staphylococci marker for multi-drug resistance • Fluoroquinolones most consistently active agents across ocular pathogens • Fluoroquinolone susceptibility profile • Gatifloxacin = Levofloxacin = Moxifloxacin • Modest diminution in S. pneumoniaesusceptibility to ciprofloxacin • Polymixin B and penicillin most limited activity

More Related